Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study

Full metadata record
DC Field Value Language
dc.contributor.authorKim, Jae-Min-
dc.contributor.authorKim, Sung-Wan-
dc.contributor.authorStewart, Robert-
dc.contributor.authorKim, Seon-Young-
dc.contributor.authorYoon, Jin-Sang-
dc.contributor.authorJung, Sung-Won-
dc.contributor.authorLee, Min-Soo-
dc.contributor.authorYim, Hyeon-Woo-
dc.contributor.authorJun, Tae-Youn-
dc.date.accessioned2021-09-07T16:27:10Z-
dc.date.available2021-09-07T16:27:10Z-
dc.date.created2021-06-14-
dc.date.issued2011-01-
dc.identifier.issn0885-6222-
dc.identifier.urihttps://scholar.korea.ac.kr/handle/2021.sw.korea/113337-
dc.description.abstractObjective To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of <= 7 sustained to 12 weeks or last follow-up, if earlier. Results For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome. Copyright (C) 2011 John Wiley & Sons, Ltd.-
dc.languageEnglish-
dc.language.isoen-
dc.publisherWILEY-
dc.subjectSTAR-ASTERISK-D-
dc.subjectMAJOR DEPRESSION-
dc.subjectOUTPATIENTS-
dc.subjectSERTRALINE-
dc.subjectANXIETY-
dc.subjectCOMORBIDITY-
dc.subjectVENLAFAXINE-
dc.subjectCITALOPRAM-
dc.subjectRECOVERY-
dc.subjectSYMPTOMS-
dc.titlePredictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study-
dc.typeArticle-
dc.contributor.affiliatedAuthorLee, Min-Soo-
dc.identifier.doi10.1002/hup.1168-
dc.identifier.scopusid2-s2.0-79953238716-
dc.identifier.wosid000288947300007-
dc.identifier.bibliographicCitationHUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, v.26, no.1, pp.41 - 50-
dc.relation.isPartOfHUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL-
dc.citation.titleHUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL-
dc.citation.volume26-
dc.citation.number1-
dc.citation.startPage41-
dc.citation.endPage50-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaNeurosciences & Neurology-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaPsychiatry-
dc.relation.journalResearchAreaPsychology-
dc.relation.journalWebOfScienceCategoryClinical Neurology-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryPsychiatry-
dc.relation.journalWebOfScienceCategoryPsychology-
dc.subject.keywordPlusSTAR-ASTERISK-D-
dc.subject.keywordPlusMAJOR DEPRESSION-
dc.subject.keywordPlusOUTPATIENTS-
dc.subject.keywordPlusSERTRALINE-
dc.subject.keywordPlusANXIETY-
dc.subject.keywordPlusCOMORBIDITY-
dc.subject.keywordPlusVENLAFAXINE-
dc.subject.keywordPlusCITALOPRAM-
dc.subject.keywordPlusRECOVERY-
dc.subject.keywordPlusSYMPTOMS-
dc.subject.keywordAuthordepression-
dc.subject.keywordAuthorremission-
dc.subject.keywordAuthoranxiety-
dc.subject.keywordAuthorparasuicide-
dc.subject.keywordAuthorKorea-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE